Floatz logo

Inno-206

Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type

Li ZhimingPhase 2/3Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

23 Active assets in the Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 2/3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Mayo Clinic
Phase 2/3BB
Cyclophosphamide
Li Zhiming
Phase 2/3BB
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3BB
Inno-206
Li Zhiming
Phase 2B

View all 24 →

Same molecule, other indications

Inno-206 is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
Recurrent Adult Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →